Literature DB >> 8304238

Role played by NK2 receptor and cyclooxygenase activation in bradykinin B2 receptor mediated-airway effects in guinea pigs.

T Sakamoto1, H Tsukagoshi, P J Barnes, K F Chung.   

Abstract

We have investigated the effects of SR-48968, an NK2 receptor antagonist, and indomethacin, a cyclooxygenase inhibitor, against bronchoconstriction and airway microvascular leakage induced by bradykinin (BK) in anesthetized guinea pigs. In addition, we have determined whether these effects were mediated via bradykinin B2 receptor activation, using a B2 receptor antagonist HOE 140. Lung resistance (RL) and extravasation of Evans blue dye into airway tissues were used as indexes of airway caliber and microvascular leakage, respectively. BK (15 nmol/kg i.v.) induced a significant increase in RL and leakage of dye at all airway levels, responses which were completely abolished by HOE 140 (0.13 mg/kg i.v.). SR-48968 (1.5 mg/kg i.v.) had no effect against BK-induced airway effects. Indomethacin (5 mg/kg i.v.) completely blocked the increase in RL and significantly inhibited the leakage of dye in peripheral intrapulmonary airway. In conclusion, bronchoconstriction induced by i.v. BK is mediated by release of cyclooxygenase products but not by stimulation of NK2 receptors, while the airway microvascular leakage only partly involves cyclooxygenase activation. Cyclooxygenase activation may occur following bradykinin B2 receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8304238     DOI: 10.1007/BF01998962

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  39 in total

1.  Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor.

Authors:  D F Rogers; S Dijk; P J Barnes
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Kinins and their antagonists.

Authors: 
Journal:  Lancet       Date:  1991-08-03       Impact factor: 79.321

3.  Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation.

Authors:  A Saria; C R Martling; Z Yan; E Theodorsson-Norheim; R Gamse; J M Lundberg
Journal:  Am Rev Respir Dis       Date:  1988-06

4.  Mechanism of action of bradykinin-induced release of prostaglandin E.

Authors:  H Juan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

Review 5.  Kinin receptor subtypes.

Authors:  D Regoli; N E Rhaleb; G Drapeau; S Dion
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

6.  Morphine, but not sodium cromoglycate, modulates the release of substance P from capsaicin-sensitive neurones in the rat trachea in vitro.

Authors:  N J Ray; A J Jones; P Keen
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

7.  Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs.

Authors:  M A Palmer; P J Piper; J R Vane
Journal:  Br J Pharmacol       Date:  1973-10       Impact factor: 8.739

8.  Bradykinin-induced bronchoconstriction in humans. Mode of action.

Authors:  R W Fuller; C M Dixon; F M Cuss; P J Barnes
Journal:  Am Rev Respir Dis       Date:  1987-01

9.  Vascular protein linkage in various tissue induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge.

Authors:  A Saria; J M Lundberg; G Skofitsch; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

10.  Bradykinin stimulates Cl secretion and prostaglandin E2 release by canine tracheal epithelium.

Authors:  G D Leikauf; I F Ueki; J A Nadel; J H Widdicombe
Journal:  Am J Physiol       Date:  1985-01
View more
  1 in total

1.  Implication of the bradykinin receptors in antigen-induced pulmonary inflammation in mice.

Authors:  Jadranka Eric; Bichoy H Gabra; Pierre Sirois
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.